Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 5:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Waldenstrom's Macroglobulinemia Refractory Clear all
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Primary Central Nervous System Lymphoma
Interventions
Ublituximab
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
8
States / cities
Huntsville, Alabama • Jonesboro, Arkansas • Athens, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2022 · Synced May 21, 2026, 5:36 PM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse, Small Lymphocytic Lymphoma, Relapsed, Waldenstrom's Macroglobulinemia Recurrent, Follicular B-cell Non-Hodgkin's Lymphoma, B-cell Lymphoma Refractory, Mantle Cell Lymphoma Recurrent, Hairy Cell Leukemia, Diffuse Large B Cell Lymphoma, Waldenstrom's Macroglobulinemia Refractory, Mantle Cell Lymphoma Refractory
Interventions
Prior MB-102 CAR-T cell investigational product., Prior MB-106 CAR-T cell investigational product.
Biological
Lead sponsor
Mustang Bio
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Orange, California • Boston, Massachusetts • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
Interventions
AVL-292
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
13
States / cities
Huntsville, Alabama • Tucson, Arizona • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
dolastatin 10
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
4
States / cities
Baltimore, Maryland • Detroit, Michigan • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 epratuzumab
Biological · Procedure · Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
4
States / cities
Belleville, New Jersey • Livingston, New Jersey • Paterson, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced May 21, 2026, 5:36 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Etentamig, Positron Emission Tomography, Questionnaire Administration
Procedure · Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Perifosine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 25, 2017 · Synced May 21, 2026, 5:36 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Lymphoma
Interventions
bortezomib, rituximab, antibody therapy, biological therapy, enzyme inhibitor therapy, monoclonal antibody therapy
Drug · Procedure
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2008 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia
Interventions
Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
15
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced May 21, 2026, 5:36 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Everolimus, Rituximab, Bortezomib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced May 21, 2026, 5:36 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Marginal Zone Lymphoma, Refractory Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia
Interventions
Carfilzomib, Laboratory Biomarker Analysis, Rituximab
Drug · Other · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced May 21, 2026, 5:36 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
714leukemia, Lymphoma
Interventions
Bortezomib, Everolimus
Drug
Lead sponsor
Brian Hill, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced May 21, 2026, 5:36 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-cell Lymphomas, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia
Interventions
Ublituximab, Lenalidomide
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Huntsville, Alabama • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Bortezomib, Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced May 21, 2026, 5:36 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
IMO-8400
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Fayetteville, Arkansas • Los Angeles, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Macroglobulinemia (WM), Other B-cell NHL Subtypes, Including WM, T-cell NHL
Interventions
CB-839, CB-839 and low dose dexamethasone, CB-839, pomalidomide, and low dose dexamethasone
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Scottsdale, Arizona • Denver, Colorado • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced May 21, 2026, 5:36 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
Interventions
Sonrotoclax, Zanubrutinib
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
17
States / cities
Duarte, California • Denver, Colorado • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
PCI-32765
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
Palo Alto, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2020 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Waldenström Macroglobulinemia
Interventions
oblimersen sodium
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
8
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Splenic Marginal Zone Lymphoma, Refractory Waldenstrom Macroglobulinemia, Richter Syndrome, Waldenstrom Macroglobulinemia
Interventions
Ibrutinib, Idelalisib, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced May 21, 2026, 5:36 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced May 21, 2026, 5:36 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia
Interventions
Ibrutinib, Ixazomib Citrate, Laboratory Biomarker Analysis, Pharmacodynamic Study, Pharmacokinetic Study
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 21, 2026, 5:36 PM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent, Mantle Cell Lymphoma Refractory, Small Lymphocytic Lymphoma, Relapsed, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory, Chronic Lymphoid Leukemia in Relapse, B-cell Lymphoma Refractory
Interventions
MB-106
Biological
Lead sponsor
Mustang Bio
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Orange, California • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced May 21, 2026, 5:36 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia, Waldenstrom's Disease, Waldenström; Hypergammaglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia of Lymph Nodes, Waldenstrom's Macroglobulinaemia, Without Mention of Remission, Waldenstrom's Macroglobulinemia Refractory
Interventions
Ibrutinib, Daratumumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced May 21, 2026, 5:36 PM EDT